Altamira Therapeutics Ltd - Warrants (29/03/2028) Operating Income

As of the most recent data (June 2023), CYTOW shows a operating income of $-1.8M. That compares with $-7.3M in the prior-year period — up 75.5% year over year. Scroll down for historical charts and peer comparison views.

Compared with the year-ago period, CYTOW's operating income is now $-1.8M (was $-7.3M) — a 75.5% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Altamira Therapeutics Ltd - Warrants (29/03/2028) is outperforming or lagging.

Tracking CYTOW's operating income over time shows whether Altamira Therapeutics Ltd - Warrants (29/03/2028) is scaling, shrinking, or reshaping that part of the business. The current reading is $-1.8M That compares with $-7.3M in the prior-year period — up 75.5% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.

Besides this operating income page, Stockcircle has Altamira Therapeutics Ltd - Warrants (29/03/2028)'s full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect operating income (currently $-1.8M) with ownership activity and broader fundamentals.

Altamira Therapeutics Ltd - Warrants (29/03/2028)'s operating income is $-1.8M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.